Systemic Sarcoidosis After Polycaprolactone Fillers Successfully Treated with Upadacitinib

Authors

  • Célestine Behaghel Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium
  • Lucie Pothen Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium https://orcid.org/0000-0001-8424-0623
  • Thomas Gérard Department of Nuclear Medicine, Cliniques universitaires Saint- Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium https://orcid.org/0000-0001-7997-3945
  • Liliane Marot Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium; Department of Pathology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium
  • Marie Baeck Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium https://orcid.org/0000-0003-0499-7939
  • Axel De Greef Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgiumx https://orcid.org/0000-0003-0713-8283

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0841

Keywords:

cosmetics, procedures, sarcoidosis, dermal fillers, polycaprolactone, upadacitinib, Janus kinase inhibitor, sarcoidosisupadacitinib

Downloads

Download data is not yet available.

References

Lin SL, Christen MO. Polycaprolactone-based dermal filler complications: A retrospective study of 1111 treatments. J Cosmet Dermatol 2020; 19: 1907–1914. DOI: https://doi.org/10.1111/jocd.13518

Philibert F, Gras-Champel V, Chaby G, Plantier F, Cartier H, Cogrel O, et al. Granulomes après injection d’Ellansé®, résolutifs sous méthotrexate. Annales de Dermatologie et de Vénéréologie 2020; 147: 525–529. DOI: https://doi.org/10.1016/j.annder.2020.02.009

Ortiz-Álvarez J, Lebrón-Martín JA, Rodríguez Fernández-Freire L, Zulueta Dorado T, García Morillo JS. Cutaneous and ganglion sarcoidosis induced by polycaprolactone facial filler: a new expression of ASIA syndrome? Eur J Case Rep Intern Med 2021; 8: 002652. DOI: https://doi.org/10.12890/2021_002652

Marcoval J, Iriarte A, Rocamora G, Mañá J. Scar sarcoidosis: Clinical features and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 2024; 41: e2024046.

Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun 2022; 13: 3140. DOI: https://doi.org/10.1038/s41467-022-30615-x

Waly YM, Sharafeldin ABK, Akhtar MU, Chilmeran Z, Fredericks S. A review of sarcoidosis etiology, diagnosis and treatment. Front Med (Lausanne) 2025; 12: 1558049. DOI: https://doi.org/10.3389/fmed.2025.1558049

Mansouri P, Farshi S. The New Frontier of JAK Inhibitors: significant therapeutic response to tofacitinib in a patient with granulomatous reaction to filler in the buttocks. J Cosmet Dermatol 2024; 23: 3924–3926. DOI: https://doi.org/10.1111/jocd.16578

Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med 2018; 379: 2540–2546. DOI: https://doi.org/10.1056/NEJMoa1805958

De Greef A, Benjelloun G, Harkemanne E, Baeck M. Successful treatment of disseminated granuloma annulare with upadacitinib. Dermatol Ther (Heidelb) 2024; 14: 813–817. DOI: https://doi.org/10.1007/s13555-024-01117-z

De Greef A, Peeters C, Dewit O, de Montjoye L, Baeck M. Upadacitinib for treatment of granulomatous cheilitis. JAMA Dermatol 2024; 160: 1001–1003. DOI: https://doi.org/10.1001/jamadermatol.2024.2378

Downloads

Published

2026-11-04

How to Cite

Behaghel, C., Pothen, L., Gérard, T., Marot, L., Baeck, M., & De Greef, A. (2026). Systemic Sarcoidosis After Polycaprolactone Fillers Successfully Treated with Upadacitinib. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0841

Issue

Vol. 106 (2026)

Section

Short Communication

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC